Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients

D. A. Perry, Morgan Hakki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Accurate determination of recipient cytomegalovirus (CMV) serostatus before allogeneic hematopoietic stem cell transplantation (HSCT) is critical, as it is the most important predictor of post-transplant CMV infection and remains associated with non-relapse mortality. The purpose of this study was to assess a recipient dual-testing strategy before HSCT. Methods: CMV serologic testing was performed before allogeneic HSCT using 2 different assays: reference laboratory (RL) and American Red Cross (ARC). In all cases, blood samples were obtained for RL testing either before ARC testing (median 130 days before HSCT [range 12–2594]) or at the same time (median 25 days before HSCT [range 8–129]). The results of serologic testing were correlated with CMV viremia post HSCT. Results: Of 287 recipients evaluated, 76 (26.5%) had discordant results, of which 74 (97.4%) tested RL−/ARC+. Ten had RL and ARC testing performed on simultaneously obtained samples, 3 of which (30%) were discordant (3 [100%] RL−/ARC+). Acute myeloid leukemia and receipt of blood product transfusion in the interval between testing were associated with RL−/ARC+ discordance. Correlation with viremia after HSCT suggested that RL−/ARC+ discordance was caused by detection of anti-CMV immunoglobulin transferred in transfused blood products and reduced specificity of the ARC assay. Conclusion: CMV-seronegative hematopoietic stem cell transplant recipients may be misclassified as seropositive if testing is performed after receipt of blood products or when using assays optimized for sensitivity at the expense of specificity. This misclassification may negatively affect post-HSCT outcomes for individual patients and studies that rely on accurate CMV serology reporting.

Original languageEnglish (US)
Pages (from-to)809-814
Number of pages6
JournalTransplant Infectious Disease
Volume18
Issue number5
DOIs
StatePublished - Oct 1 2016

Fingerprint

Red Cross
Hematopoietic Stem Cell Transplantation
Serology
Hematopoietic Stem Cells
Cytomegalovirus
Transplants
Viremia
Transplant Recipients
Cytomegalovirus Infections
Acute Myeloid Leukemia
Blood Transfusion
Immunoglobulins
Mortality

Keywords

  • cytomegalovirus
  • hematopoietic stem cell transplant
  • seroconversion
  • serology
  • testing

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients. / Perry, D. A.; Hakki, Morgan.

In: Transplant Infectious Disease, Vol. 18, No. 5, 01.10.2016, p. 809-814.

Research output: Contribution to journalArticle

@article{0862bc427a3f4098addd24c2484757d9,
title = "Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients",
abstract = "Background: Accurate determination of recipient cytomegalovirus (CMV) serostatus before allogeneic hematopoietic stem cell transplantation (HSCT) is critical, as it is the most important predictor of post-transplant CMV infection and remains associated with non-relapse mortality. The purpose of this study was to assess a recipient dual-testing strategy before HSCT. Methods: CMV serologic testing was performed before allogeneic HSCT using 2 different assays: reference laboratory (RL) and American Red Cross (ARC). In all cases, blood samples were obtained for RL testing either before ARC testing (median 130 days before HSCT [range 12–2594]) or at the same time (median 25 days before HSCT [range 8–129]). The results of serologic testing were correlated with CMV viremia post HSCT. Results: Of 287 recipients evaluated, 76 (26.5{\%}) had discordant results, of which 74 (97.4{\%}) tested RL−/ARC+. Ten had RL and ARC testing performed on simultaneously obtained samples, 3 of which (30{\%}) were discordant (3 [100{\%}] RL−/ARC+). Acute myeloid leukemia and receipt of blood product transfusion in the interval between testing were associated with RL−/ARC+ discordance. Correlation with viremia after HSCT suggested that RL−/ARC+ discordance was caused by detection of anti-CMV immunoglobulin transferred in transfused blood products and reduced specificity of the ARC assay. Conclusion: CMV-seronegative hematopoietic stem cell transplant recipients may be misclassified as seropositive if testing is performed after receipt of blood products or when using assays optimized for sensitivity at the expense of specificity. This misclassification may negatively affect post-HSCT outcomes for individual patients and studies that rely on accurate CMV serology reporting.",
keywords = "cytomegalovirus, hematopoietic stem cell transplant, seroconversion, serology, testing",
author = "Perry, {D. A.} and Morgan Hakki",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/tid.12591",
language = "English (US)",
volume = "18",
pages = "809--814",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients

AU - Perry, D. A.

AU - Hakki, Morgan

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: Accurate determination of recipient cytomegalovirus (CMV) serostatus before allogeneic hematopoietic stem cell transplantation (HSCT) is critical, as it is the most important predictor of post-transplant CMV infection and remains associated with non-relapse mortality. The purpose of this study was to assess a recipient dual-testing strategy before HSCT. Methods: CMV serologic testing was performed before allogeneic HSCT using 2 different assays: reference laboratory (RL) and American Red Cross (ARC). In all cases, blood samples were obtained for RL testing either before ARC testing (median 130 days before HSCT [range 12–2594]) or at the same time (median 25 days before HSCT [range 8–129]). The results of serologic testing were correlated with CMV viremia post HSCT. Results: Of 287 recipients evaluated, 76 (26.5%) had discordant results, of which 74 (97.4%) tested RL−/ARC+. Ten had RL and ARC testing performed on simultaneously obtained samples, 3 of which (30%) were discordant (3 [100%] RL−/ARC+). Acute myeloid leukemia and receipt of blood product transfusion in the interval between testing were associated with RL−/ARC+ discordance. Correlation with viremia after HSCT suggested that RL−/ARC+ discordance was caused by detection of anti-CMV immunoglobulin transferred in transfused blood products and reduced specificity of the ARC assay. Conclusion: CMV-seronegative hematopoietic stem cell transplant recipients may be misclassified as seropositive if testing is performed after receipt of blood products or when using assays optimized for sensitivity at the expense of specificity. This misclassification may negatively affect post-HSCT outcomes for individual patients and studies that rely on accurate CMV serology reporting.

AB - Background: Accurate determination of recipient cytomegalovirus (CMV) serostatus before allogeneic hematopoietic stem cell transplantation (HSCT) is critical, as it is the most important predictor of post-transplant CMV infection and remains associated with non-relapse mortality. The purpose of this study was to assess a recipient dual-testing strategy before HSCT. Methods: CMV serologic testing was performed before allogeneic HSCT using 2 different assays: reference laboratory (RL) and American Red Cross (ARC). In all cases, blood samples were obtained for RL testing either before ARC testing (median 130 days before HSCT [range 12–2594]) or at the same time (median 25 days before HSCT [range 8–129]). The results of serologic testing were correlated with CMV viremia post HSCT. Results: Of 287 recipients evaluated, 76 (26.5%) had discordant results, of which 74 (97.4%) tested RL−/ARC+. Ten had RL and ARC testing performed on simultaneously obtained samples, 3 of which (30%) were discordant (3 [100%] RL−/ARC+). Acute myeloid leukemia and receipt of blood product transfusion in the interval between testing were associated with RL−/ARC+ discordance. Correlation with viremia after HSCT suggested that RL−/ARC+ discordance was caused by detection of anti-CMV immunoglobulin transferred in transfused blood products and reduced specificity of the ARC assay. Conclusion: CMV-seronegative hematopoietic stem cell transplant recipients may be misclassified as seropositive if testing is performed after receipt of blood products or when using assays optimized for sensitivity at the expense of specificity. This misclassification may negatively affect post-HSCT outcomes for individual patients and studies that rely on accurate CMV serology reporting.

KW - cytomegalovirus

KW - hematopoietic stem cell transplant

KW - seroconversion

KW - serology

KW - testing

UR - http://www.scopus.com/inward/record.url?scp=84989282449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989282449&partnerID=8YFLogxK

U2 - 10.1111/tid.12591

DO - 10.1111/tid.12591

M3 - Article

C2 - 27502917

AN - SCOPUS:84989282449

VL - 18

SP - 809

EP - 814

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 5

ER -